Filing Flows › Teladoc Health (TDOC) › Q3 2026 › vs Q3 2025
Teladoc Health (TDOC) Q3 2026 vs Q3 2025 (year over year)
Teladoc Health's revenue fell $21.3M (-3%) from $626M in Q3 2025 to $605M in Q3 2026. The biggest changes: Access Fees −$54.2M (-10%); Other +$32.8M (+31%).
Teladoc Health, Q3 2026: revenue $605M (-3% year over year), operating margin -4.6%, net loss $26.9M, operating cash flow $106M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Free cash flow margin | 17.4% | 15.5% | +1.9 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Access Fees | $467M | $521M | −$54.2M | -10% |
| Other | $138M | $106M | $32.8M | +31% |
| Revenue | $605M | $626M | −$21.3M | -3% |
| Other income, net | $1.8M | $1.7M | $80K | +5% |
| Net loss | $26.9M | $49.5M | −$22.6M | -46% |
| Costs & expenses | $634M | $678M | −$44.5M | -7% |
| Operating costs | $633M | $678M | −$45.2M | -7% |
| Income tax | $655K | −$715K | $1.4M | — |
| Cost of revenue | $190M | $187M | $3.1M | +2% |
| Research & development | $65.5M | $67.6M | −$2.0M | -3% |
| Sales & marketing | $124M | $168M | −$44.0M | -26% |
| General & admin | $107M | $103M | $4.8M | +5% |
| Other operating costs | $146M | $153M | −$7.1M | -5% |
| Operating cash sources | $133M | $149M | −$15.4M | -10% |
| Share-based compensation | $11.6M | $17.0M | −$5.4M | -32% |
| Working capital & other | $122M | $132M | −$10.0M | -8% |
| Net loss absorbed | $26.9M | $49.5M | −$22.6M | -46% |
| Operating cash flow | $106M | $99.3M | $7.2M | +7% |
| Free cash flow (OCF − capex) | $105M | $97.0M | $8.3M | +9% |
| Capital expenditures | $1.2M | $2.3M | −$1.1M | -47% |
Questions
How much did Teladoc Health's revenue grow year over year in Q3 2026?
Teladoc Health's revenue fell $21.3M (-3%) from $626M in Q3 2025 to $605M in Q3 2026.
What drove Teladoc Health's revenue change in Q3 2026?
Access Fees −$54.2M (-10%); Other +$32.8M (+31%).